LIN vs ZBIO · P/E 34, rev $18.07B vs rev $10.0M
Linde plc Ordinary Shares (LIN) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the LIN and ZBIO stock pages for the full models.
Not investment advice.